Proprietary Expression PlatformExpreS2 is a durable technical asset: an insect-cell expression platform focused on complex antigens and VLP components. This capability creates a structural competitive advantage for producing difficult-to-express proteins, attracting long-term service demand and enabling differentiated vaccine development partnerships.

Service And Partnering Revenue ModelA dual revenue model—contract protein services plus partnering/licensing—provides diversified, capital-light revenue pathways. Service work can deliver steady project fees, while partnerships can supply milestone and royalty upside, offering scalable monetization if platform adoption and collaborations progress.

Low Leverage / Modest DebtVery low leverage grants financial flexibility: limited interest burden and greater capacity to raise or allocate capital for R&D or partnerships. Structurally this reduces insolvency risk and supports executing development programs while the company works to improve cash generation.

Bears Say

Consistent Negative Cash FlowPersistent negative operating and free cash flow means the business consumes cash rather than funds itself, creating structural dependence on external financing. Free cash flow worsened in 2025 (down ~13% YoY), which heightens funding risk and constrains sustained investment in growth initiatives.

Ongoing Losses And Weak MarginsRecurrent operating and net losses indicate the core business is not yet self-sustaining. Deep negative margins limit retained earnings, slow balance sheet recovery, and reduce reinvestment capacity for commercial scaling—a structural impediment to achieving durability without material revenue improvement or cost restructuring.

Contracting Equity And Asset BaseMaterial shrinkage in equity and assets over multiple years reflects accumulated losses eroding the balance sheet. This long-term capital depletion increases the likelihood of dilutive or expensive financing, undermines resilience to shocks, and raises strategic constraints on pursuing larger partnerships or internal scale-ups.

5JD0 FAQ

What was ExpreS2ion Biotech Holding AB’s price range in the past 12 months?

ExpreS2ion Biotech Holding AB lowest stock price was €1.26 and its highest was €2.52 in the past 12 months.

What is ExpreS2ion Biotech Holding AB’s market cap?

ExpreS2ion Biotech Holding AB’s market cap is €5.12M.

When is ExpreS2ion Biotech Holding AB’s upcoming earnings report date?

ExpreS2ion Biotech Holding AB’s upcoming earnings report date is May 19, 2026 which is in 85 days.

How were ExpreS2ion Biotech Holding AB’s earnings last quarter?

ExpreS2ion Biotech Holding AB released its earnings results on Feb 19, 2026. The company reported -€0.225 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.225.

Is ExpreS2ion Biotech Holding AB overvalued?

According to Wall Street analysts ExpreS2ion Biotech Holding AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does ExpreS2ion Biotech Holding AB pay dividends?

ExpreS2ion Biotech Holding AB does not currently pay dividends.

What is ExpreS2ion Biotech Holding AB’s EPS estimate?

ExpreS2ion Biotech Holding AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does ExpreS2ion Biotech Holding AB have?

ExpreS2ion Biotech Holding AB has 3,530,233 shares outstanding.

What happened to ExpreS2ion Biotech Holding AB’s price movement after its last earnings report?

ExpreS2ion Biotech Holding AB reported an EPS of -€0.225 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -12.853%.

Which hedge fund is a major shareholder of ExpreS2ion Biotech Holding AB?

Currently, no hedge funds are holding shares in DE:5JD0

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

ExpreS2ion Biotech Holding AB

ExpreS2ion Biotech Holding AB (publ), through its subsidiary, ExpreS2 ion Biotechnologies ApS, develops and produces complex proteins for vaccines and diagnostics in Denmark. The company develops capsid virus-like particle COVID-19 vaccine, which is in Phase II clinical trial. It also develops influenza and breast cancer vaccine, which is in Phase II clinical trial, as well as develops malaria vaccine. In addition, the company licenses its ExpreS2 platform to research institutes and pharmaceutical companies. ExpreS2ion Biotech Holding AB (publ) was founded in 2015 is based in Horsholm, Denmark.